Mattsson, M; Boström, C; Mihai, C; Stöcker, J; Geyh, S; Stummvoll, G; Gard, G; Möller, B; Hesselstrand, R; Sandqvist, G; Draghicescu, O; Gherghe, A M; Voicu, M; Distler, O; Smolen, J S; Stamm, T (2015). Personal factors in systemic sclerosis and their coverage by patient-reported outcome measures: A multicentre European qualitative study and literature review. European Journal of Physical and Rehabilitation Medicine, 51(4):405-421.
Finckh, A; Ciurea, A; Brulhart, L; Möller, B; Walker, U A; Courvoisier, D; Kyburz, D; Dudler, J; Gabay, C (2010). Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent? Annals of the Rheumatic Diseases, 69(2):387-393.
Dudler, J; Finckh, A; Kyburz, D; Langenegger, T; Möller, B; Schmiedel, U; Walker, U A (2010). Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis. Swiss Medical Weekly, (140):w13073.
Finckh, A; Ciurea, A; Brulhart, L; Kyburz, D; Möller, B; Dehler, S; Revaz, S; Dudler, J; Gabay, C (2007). B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis and Rheumatism, 56(5):1417-1723.